← Leaderboards
Gunnar Joerg Floris Kaufmann
Scripps Research Institute, The
$6,185,198
Attributed
$6,185,198
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2009–21$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$6,185,198 · 8
By mechanism
R42$1,997,627 · 1
R01$1,409,055 · 1
R41$1,108,756 · 3
R44$925,560 · 1
R21$519,377 · 1
R43$224,823 · 1
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Audra J Johnson$93,300
Others in their field
Top investigators on “In Vitro”
- David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Dennis R. Burton · Scripps Research Institute$79,204,175
Research focus
In VitroBaseCellsIn VivoAntibodiesPropertyBacterial InfectionsBacteriaPreventInfectionGenerationsPathogenEvaluationImmunotherapyMouse ModelPre-ClinicalSmall MoleculeResearch StudyMonoclonal AntibodiesProphylacticMemberPublic Health RelevanceAntibiotic ResistanceAffinity
Grant awards (13)
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development$925,560
R44 · FY2021 · CA · contact PI
Selective Androgen Receptor Degraders (SARDs) as new therapeutics for spinal and bulbar muscular atrophy (SBMA)$297,671
R41 · FY2021 · NS · contact PI
Human monoclonal antibodies for prevention of S. aureus infections$998,438
R42 · FY2015 · AI · contact PI
Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery$287,867
R41 · FY2015 · AI · contact PI
Human monoclonal antibodies for prevention of S. aureus infections$999,189
R42 · FY2014 · AI · contact PI
Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery$298,668
R41 · FY2014 · AI · contact PI
Human Anti-WISP1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis$224,823
R43 · FY2014 · HL · contact PI
Targeting of Myc-Max dimerization for the treatment of cancer$224,550
R41 · FY2014 · CA · contact PI
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy$465,302
R01 · FY2011 · AI · contact PI
Bacterial acyl homoserine lactones as immune modulators and drug targets$282,002
R21 · FY2011 · AI · contact PI
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy$470,003
R01 · FY2010 · AI · contact PI
Bacterial acyl homoserine lactones as immune modulators and drug targets$237,375
R21 · FY2010 · AI · contact PI
Bacterial Quorum Sensing as Target for Anti-Infective Immunotherapy$473,750
R01 · FY2009 · AI · contact PI